I ran across this comprehensive article about the emergence of new myeloma immunotherapies on OncLive.com over the weekend. It features a who's who of myeloma experts. I'm having some technical difficulties posting the article. Remember Dr. Noopur Raje? She was kind enough to fly down to speak at this year's Pat's Myeloma Beach Party. Dr.
Reality check: 21st Century Oncology just called confirming my next Kyprolis infusion on Monday. Cytoxan, Kyprolis and dex, OH MY! Updates about old friends Tom and David, news about the latest experimental myeloma therapies and a glimpse into a new, cutting edge allogeneic stem cell transplant clinical trial; last night I realized I hadn't written
I've been so busy I forgot to promote tonight's Cure Talks broadcast, featuring featured Pat's Myeloma Beach Party speaker, myeloma specialist Dr. Noopur Raje. Jenny Ahlstrom and Gary Anderson will be joining me, too. One of the things I like most about Dr. Raje: she's a researcher and patient doc. This gives her a patient-centric
I had the good fortune of dining with Dr. Noopur Raje last evening here in San Francisco. We discussed several of the studies she reviews in this CancerNetwork.com article: New Developments in Multiple Myeloma Dr. Noopur Raje – December 8, 2014 As part of our coverage of the 56th American Society of Hematology (ASH) Annual
Fellow Floridian and myeloma survivor, Gary Petersen, hosts a website, MyelomaSurvival.com. On it, Gary stresses how important it is to be treated somewhere that specializes in multiple myeloma. In a feature article that ran on MedPage Today after ASH last month, myeloma specialist, Dr. Noopur Raje, agrees: "What it really tells me is that some
The myeloma world doesn't stop turning just because I"m out of town visiting my father. Let's catch-up on a few important odds 'n ends today. First, I received an email from a reader, questioning the value of the Mayo Clinic retrospective study that Danny Parker and I reported on yesterday. The issue: the study or
A few days ago I suggested you stay tuned for news about a completely different type of therapy that focuses on a neglected 6th pathway as another way to destroy myeloma cells. I admit that the biology of myeloma cells isn’t my strong suit. But the way I understand it, myeloma researchers believe that there
I’m not going to recap what our media panel discussed on Wednesday, except to reiterate how Dr. Raje and nurse Beth’s frame of reference has forever changed how I will define “cure” when used with multiple myeloma. Dr. Noopur Raje's view that we are close to being able to keep myeloma patients alive indefinitely was
Yesterday I set the stage for Wednesday’s media panel discussion outside of Boston. Today I wanted to continue by sharing some of the things I learned from our distinguished panel. Following introductions our moderator, Anne Quinn Young, Vice President of Strategic Alliances for the Multiple Myeloma Research Foundation (MMRF), got us started with a brief
Wednesday I took part in a media press event at the Charles Hotel in historic Cambridge, Massachusetts, located just across the river from Boston. Titled Surrogates or Survival: A Discussion on Endpoints in Multiple Myeloma Clinical Trials, the panel discussion focused on the role of progression free survival (PFS) and overall survival (OS) data in
I get quite a few questions about serum-free light chain assay testing. When questions like this get technical, I refer readers to an expert. Dr. Rajkumar with Mayo Clinic has written several articles about the topic for the International Myeloma Foundation's (IMF) newsletter. But the best explanation I have ever read is by Dr.